NASDAQ:XOMAP XOMA (XOMAP) Stock Price, News & Analysis $25.41 +0.17 (+0.67%) As of 03:15 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsDividendHeadlinesSEC FilingsShort InterestTrendsBuy This Stock About XOMA Stock (NASDAQ:XOMAP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get XOMA alerts:Sign Up Key Stats Today's Range$25.38▼$25.4150-Day Range$25.23▼$27.3652-Week Range$25.14▼$30.00Volume426 shsAverage Volume2,208 shsMarket CapitalizationN/AP/E RatioN/ADividend Yield8.50%Price TargetN/AConsensus RatingN/A Company Overview XOMA Corporation (NASDAQ: XOMAP) is a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutic antibodies for autoimmune and inflammatory diseases. The company leverages proprietary antibody-generation technologies—including ribosome display and phage display—to identify and optimize human monoclonal antibodies with high specificity and favorable pharmacological profiles. Its lead clinical program is an interleukin-1 beta modulator being evaluated in patients with rare and severe inflammatory conditions. In addition to its flagship candidate, XOMA is advancing earlier-stage antibody drug candidates targeting other immune pathways in preclinical development. These efforts aim to address both orphan and more prevalent indications, reflecting the company’s commitment to delivering innovative biologics to patients with unmet medical needs. Founded in 1981 and headquartered in Berkeley, California, XOMA has cultivated strategic collaborations with major pharmaceutical partners to co-develop and license antibody programs. The company’s operations extend primarily across the United States, with regulatory and clinical development activities also underway in Europe and other regions. XOMA is led by a management team with extensive experience in antibody drug discovery and clinical development.AI Generated. May Contain Errors. Read More Receive XOMAP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for XOMA and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. XOMAP Stock News HeadlinesHC Wainwright & Co. downgrades XOMA Royalty (XOMA)April 30, 2026 | msn.comLGND: XOMA Buy Adds 100+ AssetsApril 29, 2026 | finance.yahoo.comYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account.May 5 at 1:00 AM | Profits Run (Ad)Ligand to buy XOMA Royalty for $39/shareApril 27, 2026 | msn.comWe Believe XOMA Royalty's (NASDAQ:XOMA) Earnings Are A Poor Guide For Its ProfitabilityMarch 26, 2026 | finance.yahoo.comXOMA Royalty Corporation: XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business AchievementsMarch 18, 2026 | finanznachrichten.deXOMA shares climb after Q4 results top forecasts on strong royalty incomeMarch 18, 2026 | msn.comXOMAP XOMA Royalty Corporation 8.625% CUM PERP PFD SER AMarch 5, 2026 | seekingalpha.comSee More Headlines XOMAP Stock Analysis - Frequently Asked Questions How have XOMAP shares performed this year? XOMA's stock was trading at $26.8690 on January 1st, 2026. Since then, XOMAP stock has decreased by 5.4% and is now trading at $25.41. How do I buy shares of XOMA? Shares of XOMAP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Record date for 4/15 Dividend4/02/2026Ex-Dividend for 4/15 Dividend4/02/2026Dividend Payable4/15/2026Today5/05/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1w+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 For the last 8 days, XOMAP's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:XOMAP CIK791908 Webwww.xoma.com Phone510-204-7200FaxN/AEmployees10Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$11.66 million Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The 10 Best AI Stocks to Own in 2026Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:XOMAP) was last updated on 5/5/2026 by MarketBeat.com Staff. From Our PartnersIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredThe $1.75T "Backdoor" ticker (NOT Starlink)When the SpaceX IPO launches, most investors will already be too late. The real opportunity isn't the IPO itse...Behind the Markets | SponsoredSell 99% of Your Stocks, Do THIS Instead…Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...The Oxford Club | SponsoredTrade this between 9:30 and 10:45 am ESTThe first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...Base Camp Trading | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredElon Unveils AI Passive Income Stream for Millions of AmericansDuring Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding XOMA Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share XOMA With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
